STOCK TITAN

Seres Therapeutics Inc SEC Filings

MCRB NASDAQ

Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Seres Therapeutics, Inc. filings document the disclosure record of a Nasdaq-listed biotechnology company focused on live biotherapeutic and microbiome-based therapeutic programs. Its Form 8-K reports furnish quarterly and annual financial results, operational updates, Regulation FD corporate presentations, and material-event disclosures involving pipeline priorities, clinical and regulatory matters, capital allocation, cost-reduction actions, and financing or partnership activity.

The company’s proxy materials cover annual meeting mechanics, stockholder voting, board governance, executive compensation, and equity-award information. SEC filings also identify Seres’ common stock registered under the Exchange Act and traded on the Nasdaq Global Select Market under the symbol MCRB.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Seres Therapeutics (MCRB) SEC filings are available on StockTitan?

StockTitan tracks 43 SEC filings for Seres Therapeutics (MCRB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Seres Therapeutics (MCRB)?

The most recent SEC filing for Seres Therapeutics (MCRB) was filed on July 2, 2025.